Onda-Tabita CALUGARU, Mihaela DRAGOMIR, Silvia APOSTEANU, Cerasela JARDAN, Alina Cristiana MEIROSU, Daniel CORIU
Acute Promyelocytic Leukemia (APL) is a hematological emergency. Despite the high remission rate, APL therapy, represented by all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO), can lead to severe adverse effects and death. Considering these facts, there is a need to develop a new effective therapeutic line with reduced cytotoxicity and new biomarkers that are more sensitive for disease onset and progression.
https://doi.org/10.59854/dhrrh.2023.1.2.37
